Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Matinas Biopharma(MTNB) the EBIT is -1.555 M (+15.35%);the EPS is -0.207 (+79.92%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.00B15.35%
----
----
EPS
-0.20779.92%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf